中国淋巴瘤治疗指南(2023年版)

Clinical practice guideline for lymphoma in China(2023 version)

淋巴瘤是中国常见的恶性肿瘤之一。预计2022年中国新发霍奇金淋巴瘤6984例,死亡2948例;新发非霍奇金淋巴瘤97788例,死亡57929例。淋巴瘤病理类型复杂,异质性强,治疗原则各有不同。近年来,随着人们对淋巴瘤本质认识的不断深入,淋巴瘤在诊断和治疗方面出现了很多新的研究结果,患者生存得到了改善。为了及时反映国内外淋巴瘤治疗领域的进展,进一步提高中国淋巴瘤的规范化诊断和治疗水平,中国医疗保健国际交流促进会肿瘤内科学分会、中国抗癌协会淋巴瘤专业委员会和中国医师协会肿瘤医师分会组织专家编写了《中国淋巴瘤治疗指南(2023年版)》。

Lymphoma is one of the most common malignancies in China.In China,there are estimated 6984 new Hodgkin lymphoma cases and 2948 deaths in 2022,with 97788 new non-Hodgkin lymphoma cases and 57929 deaths.Due to the complicated pathological subtypes and heterogeneity,the treatment strategies for lymphoma vary largely.In recent years,with the deeper understanding for the nature of lymphoma,much research progress has been achieved in the diagnosis and treatment,leading to a remarkable improvement in survival outcome of patients.In order to update the progress in the treatment of lymphoma worldwide timely,and further improve the level of standardized diagnosis and treatment of lymphoma in China,the Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare,the China Anti-cancer Association Lymphoma Committee,and the Chinese Association for Clinical Oncologists organized experts to formulate"Clinical practice guideline for lymphoma in China(2023 version)".